-
Price Momentum
DMRA is trading in the middle of its 52-week range and below its 200-day simple moving average.
-
Price change
The price of DMRA shares has increased $1.84 since the market last closed. This is a 8.42% rise.
-
Closed at $23.70.
The stock has remained unchanged in after-hours trading.
Key terms
About DMRA
Damora Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Waltham, MA.
-
Market cap: $1.47B
A market capitalization between $300 million and $2 billion places DMRA in the small capitalization category.
Key terms
Smart score
Latest DMRA news
DMRA Financials
-
DMRA total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
Net income: -$209.84M (1Y), -$31.99M (Q3)
Net Income decreased 878.77% since last year and increased 2.62% since last quarter.
-
Earnings per share: -$152.99 (1Y), -$0.52 (Q3)
EPS decreased 725.75% since last year and increased 1.47% since last quarter.
Key terms
DMRA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DMRA Competitors
-
How competitors are chosen
DMRA's competitors are included in the Health Technology sector and Pharmaceuticals: Major group
-
Market cap: $1.47B
A market capitalization between $300 million and $2 billion places DMRA in the small capitalization category.
